Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Poster details at the ASGCT 25th Annual Meeting Poster details at the ASGCT 25th Annual Meeting About Coave Therapeutics Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases. Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare...

Poster details at the ASGCT 25th Annual Meeting

About Coave Therapeutics

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.

Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

The Company is advancing a pipeline of novel therapies targeting CNS and eye diseases where targeted gene therapy using chemically-modified AAVs has the potential to be most effective.

Coave Therapeutics, which is headquartered in Paris (France), is backed by leading international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne.

For more information, please visit www.coavetx.com or follow us on LinkedIn www.linkedin.com/company/coavetx/

CONTACTS

Coave Therapeutics
Rodolphe Clerval, CEO
[email protected]

MEDiSTRAVA Consulting

Sylvie Berrebi, Eleanor Perkin, Mark Swallow
[email protected]
Tel: +44 (0)203 928 6900